Shock State Clinical Trial
Official title:
Investigations of New Markers in Patients With Shock
Shock is a severe deficiency in oxygen at the cell level which could lead to the death.The study was aimed at finding markers of treatment response in patients with shock, with a better accuracy than that of lactate actually used : hypoxia-inducible factor (HIF), circulating DNA (cDNA), and plasma from cells (MPs).
Shock is a severe deficiency in oxygen at the cell level which could lead to the death. The
treatment strategy relies on the profile of plasma lactate level, which the kinetics and
metabolism are inadequate for evaluating the treatment efficiency without delay. Hence, it
is now critical to identify adequate markers of dysoxia.
The study was aimed at finding markers of treatment response in patients with shock, with a
better accuracy than that of lactate.To this purpose, a multiple approach is undertaken with
the analysis of 3 independent markers of cellular ischemia : hypoxia-inducible factor (HIF),
circulating DNA (cDNA), and plasma from cells (MPs). Indeed, the characteristics of HIF as
marker of cell dysoxia, and MPs as markers of cell apoptosis, combined with cDNA seem
providing complementary information in order to describe the consequences of shock as well
as the response to treatment.
Samples of patients will be collected (from rest of blood sample collected for other
measurements) at each step of the management of these patients. The evolution of these
markers will be compared with that of lactate plasma levels (standard of care). Subgroup
analysis will be undertaken in relation with the cause of shock state (septic, cardiogenic,
hemorrhagic).
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention